Last 46 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.12 | — | — | — | — | — | — | — | — | — | 0.09 | 0.43 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 3.76 | 52.03 | 133.60 | 14.00 | 0.60 | 7.44 | 2.86 | 0.76 | 2.31 | 3.29 | 5.30 | 66.63 | 66.43 | 100.95 | 681.39 | 101.42 | 37.74 | 287.91 | 189.27 | 392.49 | 334.78 |
| — | +599.5% | +4576.7% | +1751.8% | -74.0% | +126.2% | -46.1% | -98.9% | -96.5% | -96.7% | -99.2% | -34.3% | +76.0% | -64.9% | +260.0% | -74.2% | -88.7% | -45.6% | -41.3% | -3.5% | +15855.3% | |
| P/B Ratio | 1.92 | 1.59 | 29.36 | 0.30 | 0.15 | 0.12 | 0.06 | 0.07 | 0.08 | 0.03 | 0.04 | 0.64 | 1.38 | 0.94 | 0.98 | 0.69 | 0.58 | 0.91 | 0.18 | — | — |
| — | +1216.6% | +50525.2% | +323.5% | +97.3% | +281.4% | +41.7% | -88.9% | -94.5% | -96.6% | -95.8% | -7.8% | +139.3% | +2.5% | +459.1% | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | -0.06 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 93.4% | 68.1% | 91.7% | 10.4% | 97.1% | 88.4% | 92.3% | 92.2% | 92.7% | 100.0% | -121.3% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| — | -22.9% | -0.7% | -88.7% | +4.8% | -11.6% | +176.1% | -7.8% | -7.3% | 0.0% | -221.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin | -4350.1% | -14612.6% | -19516.8% | -31432.3% | -1089.8% | -19230.1% | -6212.8% | -979.0% | -2770.8% | -11740.7% | -16687.5% | -10112.2% | -4831.9% | -18463.6% | -126537.9% | -15895.5% | -6510.0% | -31586.2% | -80185.3% | -46108.6% | -23701.8% |
| — | +24.0% | -214.1% | -3110.6% | +60.7% | -63.8% | +62.8% | +90.3% | +42.7% | +36.4% | +86.8% | +36.4% | +25.8% | +41.5% | -57.8% | +65.5% | +72.5% | +62.2% | -1495.3% | -1033.3% | -875.6% | |
| Net Margin | -3959.4% | -9298.3% | -16365.5% | -25748.1% | -875.8% | -21359.2% | -3778.6% | -467.2% | -4521.4% | -6352.2% | 6075.5% | 15531.8% | -8851.8% | -22915.6% | -117501.4% | -16054.6% | -6575.6% | -30100.9% | -408062.8% | -52302.9% | -27084.0% |
| — | +56.5% | -333.1% | -5411.0% | +80.6% | -236.3% | -162.2% | -103.0% | +48.9% | +72.3% | +105.2% | +196.7% | -34.6% | +23.9% | +71.2% | +69.3% | +75.7% | +65.4% | -1104.1% | -838.2% | -278.9% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -320.5% | -127.4% | -250.2% | -86.2% | -48.3% | -72.8% | -17.7% | -10.5% | -31.8% | -18.1% | 10.3% | 37.8% | -44.1% | -60.3% | -31.9% | -26.2% | -24.1% | -23.1% | -244.1% | — | — |
| — | -75.1% | -1316.5% | -720.7% | -51.8% | -301.1% | -272.0% | -127.8% | +27.8% | +69.9% | +132.2% | +244.5% | -82.7% | -161.5% | +86.9% | — | — | — | — | — | — | |
| ROA | -174.1% | -49.4% | -66.0% | -42.9% | -28.2% | -47.2% | -12.2% | -7.1% | -23.6% | -14.5% | 8.9% | 35.2% | -41.7% | -47.0% | -25.3% | -24.9% | -23.2% | -22.2% | -165.7% | -165.4% | -123.4% |
| — | -4.6% | -441.5% | -503.4% | -19.2% | -224.7% | -237.2% | -120.2% | +43.3% | +69.1% | +135.1% | +241.2% | -80.0% | -111.7% | +84.7% | +84.9% | +81.2% | +94.3% | +16.9% | -200.8% | -164.2% | |
| ROIC | -343.7% | — | -1274.8% | -113.7% | -60.4% | -55.9% | -24.4% | -20.0% | -16.8% | -27.1% | -24.3% | -21.7% | -20.5% | -41.7% | -35.8% | -58.7% | -309.8% | -307.2% | -382.7% | -2056.5% | — |
| — | — | -5121.8% | -469.1% | -260.6% | -106.4% | -0.4% | +8.0% | +18.4% | +35.0% | +32.0% | +63.0% | +93.4% | +86.4% | +90.7% | +97.1% | — | +94.2% | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | 0.01 | — | — | — | — | — | 0.00 | 0.01 | 0.01 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.02 | 0.02 | 0.02 | 0.03 | — | — |
| — | — | — | — | — | — | — | -72.6% | -59.0% | -57.2% | -44.6% | -20.8% | -3.4% | +2.2% | -5.6% | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 0.84 | 2.35 | 0.84 | 1.37 | 2.07 | 2.24 | 2.97 | 2.95 | 2.82 | 4.86 | 4.37 | 13.51 | 14.82 | 27.18 | 2.53 | 23.55 | 29.47 | 40.25 | 59.01 | 1.34 | 1.38 |
| — | +5.2% | -71.7% | -53.6% | -26.6% | -54.0% | -31.9% | -78.2% | -81.0% | -82.1% | +72.7% | -42.6% | -49.7% | -32.5% | -95.7% | +1658.5% | +2037.4% | +1904.2% | +1834.4% | +758.3% | +253.2% | |
| Quick Ratio | 0.84 | 2.35 | 0.84 | 1.37 | 2.07 | 2.24 | 2.97 | 2.95 | 2.82 | 4.86 | 4.37 | 13.51 | 14.82 | 27.18 | 2.53 | 23.55 | 29.47 | 40.25 | 59.01 | 1.34 | 1.38 |
| — | +5.2% | -71.7% | -53.6% | -26.6% | -54.0% | -31.9% | -78.2% | -81.0% | -82.1% | +72.7% | -42.6% | -49.7% | -32.5% | -95.7% | +1658.5% | +2037.4% | +1904.2% | +1834.4% | +758.3% | +253.2% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | 7.66 | — | — | — | — | -160.43 | -99.30 | -165.01 | -94.42 | -7.44 | -7.01 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 46 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BRTX stock.
BioRestorative Therapies, Inc.'s current P/E is -0.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
BioRestorative Therapies, Inc.'s current operating margin is -4350.1%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking BioRestorative Therapies, Inc.'s business trajectory between earnings reports.